🎉 M&A multiples are live!
Check it out!

Ovid Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Ovid Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Ovid Therapeutics Overview

About Ovid Therapeutics

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.


Founded

2014

HQ

United States of America
Employees

23

Website

ovidrx.com

Financials

LTM Revenue $0.5M

LTM EBITDA n/a

EV

-$17.9M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Ovid Therapeutics Financials

Ovid Therapeutics has a last 12-month revenue of $0.5M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Ovid Therapeutics achieved revenue of $0.6M and an EBITDA of -$61.3M.

Ovid Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Ovid Therapeutics valuation multiples based on analyst estimates

Ovid Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.4M $0.6M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$57.7M -$61.3M XXX XXX XXX
EBITDA Margin -14727% -10825% XXX XXX XXX
Net Profit -$54.2M -$52.3M XXX XXX XXX
Net Margin -13829% -9247% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Ovid Therapeutics Stock Performance

As of April 15, 2025, Ovid Therapeutics's stock price is $0.

Ovid Therapeutics has current market cap of $20.4M, and EV of -$17.9M.

See Ovid Therapeutics trading valuation data

Ovid Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$17.9M $20.4M XXX XXX XXX XXX $-0.43

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Ovid Therapeutics Valuation Multiples

As of April 15, 2025, Ovid Therapeutics has market cap of $20.4M and EV of -$17.9M.

Ovid Therapeutics's trades at -36.9x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Ovid Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Ovid Therapeutics and 10K+ public comps

Ovid Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$17.9M XXX XXX XXX
EV/Revenue -31.7x XXX XXX XXX
EV/EBITDA 0.3x XXX XXX XXX
P/E -0.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Ovid Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Ovid Therapeutics Valuation Multiples

Ovid Therapeutics's NTM/LTM revenue growth is -40%

Ovid Therapeutics's revenue per employee for the last fiscal year averaged $25K, while opex per employee averaged $2.7M for the same period.

Over next 12 months, Ovid Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Ovid Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Ovid Therapeutics and other 10K+ public comps

Ovid Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 45% XXX XXX XXX XXX
EBITDA Margin -10825% XXX XXX XXX XXX
EBITDA Growth 6% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -10865% XXX XXX XXX XXX
Revenue per Employee $25K XXX XXX XXX XXX
Opex per Employee $2.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 4538% XXX XXX XXX XXX
R&D Expenses to Revenue 6496% XXX XXX XXX XXX
Opex to Revenue 11034% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Ovid Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Ovid Therapeutics M&A and Investment Activity

Ovid Therapeutics acquired  XXX companies to date.

Last acquisition by Ovid Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Ovid Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Ovid Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Ovid Therapeutics

When was Ovid Therapeutics founded? Ovid Therapeutics was founded in 2014.
Where is Ovid Therapeutics headquartered? Ovid Therapeutics is headquartered in United States of America.
How many employees does Ovid Therapeutics have? As of today, Ovid Therapeutics has 23 employees.
Who is the CEO of Ovid Therapeutics? Ovid Therapeutics's CEO is Mr. Jeremy M. Levin, D.Phil.,M.B..
Is Ovid Therapeutics publicy listed? Yes, Ovid Therapeutics is a public company listed on NAS.
What is the stock symbol of Ovid Therapeutics? Ovid Therapeutics trades under OVID ticker.
When did Ovid Therapeutics go public? Ovid Therapeutics went public in 2017.
Who are competitors of Ovid Therapeutics? Similar companies to Ovid Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Ovid Therapeutics? Ovid Therapeutics's current market cap is $20.4M
What is the current revenue of Ovid Therapeutics? Ovid Therapeutics's last 12-month revenue is $0.5M.
What is the current EV/Revenue multiple of Ovid Therapeutics? Current revenue multiple of Ovid Therapeutics is -36.9x.
What is the current revenue growth of Ovid Therapeutics? Ovid Therapeutics revenue growth between 2023 and 2024 was 45%.
Is Ovid Therapeutics profitable? Yes, Ovid Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.